Common diabetes drug tested as new hope for scarring kidney disease
NCT ID NCT06090227
Summary
This study is testing if adding the drug metformin to standard care helps protect specialized kidney cells in people with FSGS, a disease that causes kidney scarring. Researchers want to see if metformin can reduce cell injury and slow disease progression over six months. The trial will enroll 30 adults already receiving standard steroid treatment for their FSGS.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
Contact
Contact
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.